BCP-ALL cells were cultured with either OP9-Gal3-KO or OP9-EV control stroma in the presence of 5 nM vincristine, part of the standard cytotoxic therapy in BCP-ALL (Vin, to treat Ph- US7 cells) or 20 nM of the targeted tyrosine kinase inhibitor nilotinib (Nilo, to treat Ph+ TXL2 cells) for >15 days. This evidence concerns the gene LGALS3 and acute lymphoblastic leukemia.